Search Ontology:
ChEBI
3-{beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-Glc-(1->6)-beta-D-Glc-(1->6)-beta-D-Glc-yl}-1,2-dimyristoyl-sn-glycerol
- Term ID
- CHEBI:150019
- Synonyms
-
- (2R)-2-{[(2R,3R,4R,5S,6R)-3-acetamido-4-{[(2S,3R,4R,5S,6R)-3-acetamido-6-({[({(2R,3S,4R,5R,6R)-5-acetamido-4-{[(2S,3R,4R,5S,6R)-3-acetamido-6-({[({(2R,3S,4R,5R,6R)-5-acetamido-4-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-p
- 3-{2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->3)-[(1S)-1-carboxy-2-hydroxyethyl-(1->1)]-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(6-phospho-6)-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->3)-[(1S)-1-carboxy-2-hydroxyethyl-(1->1)]-2-acetamido-2-deoxy-
- 3-{beta-D-GlcpNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcpNAc-(6-P-6)-beta-D-GlcpNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcpNAc-(6-P-6)-beta-D-GlcpNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcpNAc-(6-P-6)-beta-D-Glcp-(1->6)-beta-D-Glcp-(1->6)-beta-D-Glcp-yl}-1,2-dimyristoyl-sn
- WH237
- Definition
- A glycosylglycerol derivative in which the glycosyl moiety of glycosyl-sn-glycerol is N-acetyl-beta-D-glucosaminyl-(1->3)-[(D-glyceric acid)-(2->1)]-beta-D-glucosaminyl-(6-phospho-6)-N-acetyl-beta-D-glucosaminyl-(1->3)-[(D-glyceric acid)-(2->1)]-beta-D-glucosaminyl-(6-phospho-6)-N-acetyl-beta-D-glucosaminyl-(1->3)-[(D-glyceric acid)-(2->1)]-beta-D-glucosaminyl-(6-phospho-6)-beta-D-glucosyl-(1->6)-beta-D-glucosyl-(1->6)-beta-D-glucosyl attached at O-3, with O-1 and O-2 both carrying myristoyl substituents. Synthetic C. difficile lipoteichoic acid (LTA) molecule consisting of lipid + core region and three [(->6)-alpha-D-GlcpNAc-(1->3)-[P-6]-alpha-D-GlcpNAc-(1->2)-D-GroA polymeric repeats (where P-6 is a phosphodiester bridge and GroA is glyceric acid).
- References
- Ontology
- ChEBI ( EBI )
- is a type of
-
- has_functional_parent
-
Phenotype
Phenotype resulting from 3-{beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-Glc-(1->6)-beta-D-Glc-(1->6)-beta-D-Glc-yl}-1,2-dimyristoyl-sn-glycerol
Phenotype where environments contain 3-{beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-Glc-(1->6)-beta-D-Glc-(1->6)-beta-D-Glc-yl}-1,2-dimyristoyl-sn-glycerol
Phenotype modified by environments containing 3-{beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-Glc-(1->6)-beta-D-Glc-(1->6)-beta-D-Glc-yl}-1,2-dimyristoyl-sn-glycerol
Human Disease Model